Moreover, GEO clinical data shows that the expression of ADRB2 does not show significant changes in hepatitis B, hepatitis C, and drug-induced liver injury, suggesting that ADRB2 may be a specific biomarker for AH (Supplementary Figure S1). Here, ADRB2 is linked to hepatitis B virus infection.